# Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer

> **NCT05751265** · PHASE2 · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 39 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** 5Fu
- **DRUG:** Paclitaxel injection

## Key facts

- **NCT ID:** NCT05751265
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-01
- **Primary completion:** 2024-06-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05751265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05751265, "Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05751265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*